Amjevita Injection
Product Images NDC 55513-400

Product Visual Gallery

This gallery contains 42 technical images submitted to the FDA as part of the official labeling for Amjevita (NDC 55513-400). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amgen, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Amjevita 01)

A line graph showing the percent of ACR 20 responders over time in weeks for AMJEVITA 40 mg every other week compared to placebo. The x-axis represents time in weeks (0 to 48), and the y-axis represents the percent of responders (0 to 70%). The graph shows a higher response rate for AMJEVITA than placebo throughout the study period.*

FDA Label Image

Figure 2 (Amjevita 02)

A line graph comparing the percentage of ASAS 20 Response over time in weeks between two groups: Placebo (N=107) and Adalimumab (N=208). The graph shows a higher response rate for the Adalimumab group compared to the Placebo group throughout the 24-week period.*

FDA Label Image

Image (Amjevita 03)

An instructional diagram of an AMJEVITA (adalimumab-atto) injection pen showing a blue start button at the top, an expiration date section, a window that indicates medicine presence, and a yellow cap on the bottom. The pen is designed for subcutaneous injection.*

FDA Label Image

Image (Amjevita 04)

An illustrated diagram of the AMJEVITA (adalimumab-atto) subcutaneous injection pen. The pen features a yellow safety guard, a yellow cap that is removed before use, and a yellow window indicating injection completion. The expiration date and a numeric code are shown on the pen label.*

FDA Label Image

Image (Amjevita 05)

An instructional diagram showing a blue injection pen with a yellow cap. The pen has labeled parts including the cap, a window, and the medicine inside. The image highlights the yellow cap on the pen and the visible medicine through the window.*

FDA Label Image

Image (Amjevita 06)

An instructional illustration showing components related to administration of a subcutaneous injection. It includes a blue injection pen device, three cotton balls, an alcohol wipe packet, a skin adhesive bandage, and a red biohazard sharps disposal container with its lid open.*

FDA Label Image

Image (Amjevita 07)

An anatomical diagram showing recommended subcutaneous injection sites for AMJEVITA (adalimumab-atto) on the human body. The illustration highlights the stomach area (abdomen) and thigh as appropriate injection locations for this medication.*

FDA Label Image

Image (Amjevita 08)

Instructional illustration showing a person holding an AMJEVITA injection pen and removing the yellow protective cap from the needle end, demonstrating a step in preparing the adalimumab-atto subcutaneous injection for use.*

FDA Label Image

Image (Amjevita 09)

An instructional illustration showing a person administering a subcutaneous injection to the thigh. The image depicts one hand pinching the skin on the thigh while the other hand presses down, with arrows indicating the direction of skin pinching or injection placement.*

FDA Label Image

Image (Amjevita 10)

AMJEVITA 40 mg/0.8 mL subcutaneous injection vial label by Amgen, Inc. The label shows dosage strength, drug name adalimumab-atto, barcode, lot number, expiration date, and storage instructions. The vial is color-coded with blue and green accents.*

FDA Label Image

Image (Amjevita 11)

An instructional anatomical illustration showing a person pinching the skin of their abdomen, likely demonstrating the technique for subcutaneous injection. The image highlights the skin being lifted between fingers with arrows indicating the pinching and pulling motion.*

FDA Label Image

Image (Amjevita 12)

Illustration showing the proper technique for subcutaneous injection using an injection pen labeled AMJEVITA, demonstrating the pen held at a 90-degree angle to the skin for administration.*

FDA Label Image

Image (Amjevita 13)

An instructional illustration showing a person administering AMJEVITA (adalimumab-atto) via subcutaneous injection using a blue autoinjector. One hand holds the autoinjector perpendicular to the skin, while the other hand stabilizes the injection site.*

FDA Label Image

Image (Amjevita 14)

An instructional illustration showing a blue injection pen being pressed against the skin at an angle, with an arrow pointing downward to indicate the direction of injection for subcutaneous administration.*

FDA Label Image

Image (Amjevita 15)

An instructional illustration showing a hand holding a blue prefilled injection pen labeled with a dosage of 10 mg/.2 mL, positioned above a person's skin on the abdomen, demonstrating the subcutaneous injection process with a 'click' sound effect indicating activation.*

FDA Label Image

Image (Amjevita 16)

An instructional illustration showing a hand holding an injection device vertically and pressing it onto a person's skin, with the other hand stabilizing the injection site. A "click" sound is indicated, suggesting activation of the device for subcutaneous administration.*

FDA Label Image

Image (Amjevita 17)

An instructional illustration showing a blue injection pen with a visible liquid window. A circular timer graphic indicates approximately 10 seconds, likely suggesting the wait time during an injection or preparation step.*

FDA Label Image

Image (Amjevita 18)

FDA Label Image

Image (Amjevita 19)

An instructional illustration showing a hand holding a blue injection pen labeled for AMJEVITA (adalimumab-atto) being placed into a red biohazard sharps disposal container. A black arrow indicates the direction of disposal, emphasizing safe disposal of the injection pen after use.*

FDA Label Image

Image (Amjevita 20)

An instructional diagram of an AMJEVITA injection pen showing labeled parts including a blue start button, expiration date area, a window displaying the medicine inside, and a yellow cap at the bottom of the pen.*

FDA Label Image

Image (Amjevita 21)

An instructional diagram showing recommended subcutaneous injection sites on a human body. The labeled areas for injection include the stomach area (abdomen) and the front of the thighs.*

FDA Label Image

Image (Amjevita 22)

Instructional illustration showing two subcutaneous injection sites for AMJEVITA (adalimumab-atto) injection: the thigh and the abdomen. Each site is depicted with a hand administering an injection using a syringe or pen device, indicating proper injection technique for subcutaneous administration.*

FDA Label Image

Image (Amjevita 23)

An instructional illustration showing a hand holding an Amjevita prefilled syringe, preparing to remove the yellow cap from the needle end. The image depicts the step for syringe preparation prior to subcutaneous injection.*

FDA Label Image

Image (Amjevita 24)

An instructional illustration showing a hand holding a pen-like injector device positioned above the skin, with an arrow pointing downward labeled "Push down," indicating where to press the device for subcutaneous injection.*

FDA Label Image

Image (Amjevita 25)

An instructional illustration demonstrating the use of a subcutaneous injection pen. The image shows a hand holding the pen vertically against the skin of an abdomen, with a "click" sound indicated, signifying activation of the injection device.*

FDA Label Image

Image (Amjevita 26)

An instructional illustration showing the use of a subcutaneous injection device. It depicts one hand holding an injection pen and pressing it against the skin on the forearm with a "click" sound effect. A timer circle indicates a wait period, and a close-up shows the injection window with a yellow indicator.*

FDA Label Image

Image (Amjevita 27)

An instructional diagram illustrating the parts of a prefilled syringe for AMJEVITA (adalimumab-atto) injection. The labeled components include the plunger rod, finger flange, label and expiration date area, syringe barrel containing the medicine, and needle cap on the bottom. This is a subcutaneous injection device.*

FDA Label Image

Image (Amjevita 28)

An illustration showing labeled parts of a used injection syringe for AMJEVITA (adalimumab-atto). The diagram identifies the used plunger rod, finger flange, label and expiration date on the barrel, used syringe barrel, used needle, and needle cap off.*

FDA Label Image

Image (Amjevita 29)

Illustration showing a hand holding alternating doses of prefilled injection syringes from a package, suggesting the use of subcutaneous injection syringes, likely for AMJEVITA (adalimumab-atto) in various available strengths.*

FDA Label Image

Image (Amjevita 30)

An instructional illustration depicting two hands removing an Amjevita 40 mg/.8 mL prefilled syringe from its packaging tray, with red arrows indicating the direction to pull the syringe upwards and out of the tray.*

FDA Label Image

Image (Amjevita 31)

An instructional diagram of a prefilled syringe for Amjevita (adalimumab-atto) injection, showing labeled parts including needle cap on, syringe barrel containing medicine, label and expiration date area, plunger rod, and finger flange for handling.*

FDA Label Image

Image (Amjevita 32)

Illustration showing a subcutaneous injection setup including a prefilled syringe, cotton balls, adhesive bandage, and a red biohazard sharps disposal container. The image represents components commonly used for administering AMJEVITA (adalimumab-atto) injection by subcutaneous route.*

FDA Label Image

Image (Amjevita 33)

An instructional illustration showing recommended injection sites on a human body for subcutaneous administration. Highlighted areas include the stomach (abdomen) and the thigh. The image is relevant for subcutaneous injectable drugs like AMJEVITA (adalimumab-atto).*

FDA Label Image

Image (Amjevita 34)

An instructional illustration showing two hands preparing a syringe for injection. The top hand is pulling the cap off the needle straight up, indicating the removal of a protective cover from the syringe needle, while the bottom hand holds the syringe barrel. This diagram demonstrates safe syringe handling prior to subcutaneous injection.*

FDA Label Image

Image (Amjevita 35)

An instructional illustration showing a person pinching the skin on the abdomen, demonstrating the preparation for a subcutaneous injection likely related to administering the AMJEVITA (adalimumab-atto) injection.*

FDA Label Image

Image (Amjevita 36)

An instructional diagram showing the proper technique for subcutaneous injection. The illustration depicts a hand holding a syringe inserted at a 90-degree angle into the skin, with a dashed line indicating an alternative 45-degree angle for needle insertion.*

FDA Label Image

Image (Amjevita 37)

Illustration showing the administration of Amjevita (adalimumab-atto) injection by subcutaneous injection. The image depicts one hand holding a syringe and injecting into the skin of the abdomen while the other hand stretches the skin, demonstrating the subcutaneous injection technique.*

FDA Label Image

Image (Amjevita 38)

An instructional illustration showing a hand holding a syringe for subcutaneous injection. The syringe is positioned with the needle pointing downward, near the skin of the other hand, indicating the injection technique for AMJEVITA (adalimumab-atto) subcutaneous injection.*

FDA Label Image

Image (Amjevita 39)

Illustration showing a hand placing a syringe with a needle into a red sharps disposal container marked with a biohazard symbol, demonstrating the safe disposal of injection needles.*

FDA Label Image

Principal Display Panel (20 mg Syringe Carton)

AMJEVITA 20 mg/0.4 mL subcutaneous injection carton label. The label displays the proprietary name AMJEVITA with the generic name adalimumab-atto. It indicates a single-dose prefilled syringe containing 20 mg/0.4 mL of sterile solution with no preservatives. Storage instructions specify refrigeration at 2°C to 8°C (36°F to 46°F), with warnings against freezing and shaking. The label notes it is for pediatric use in patients 15 to less than 30 kg and is manufactured by Amgen, Inc.*

FDA Label Image

Principal Display Panel (40 mg Syringe Carton)

AMJEVITA 40 mg/0.8 mL injection packaging label for subcutaneous use. The label shows the brand and generic name (adalimumab-atto), states it is a sterile solution with no preservative, and includes storage instructions to keep refrigerated at 2 to 8°C. The package contains one single-dose prefilled syringe and is labeled by Amgen, Inc. The label also notes it is not made with natural rubber latex.*

FDA Label Image

Principal Display Panel (40 mg Autoinjector Carton)

AMJEVITA 40 mg/0.8 mL injection in a SureClick Prefilled Autoinjector for subcutaneous use. The sterile solution contains no preservative and is packaged as a single-dose autoinjector. The label includes storage instructions, warnings about storage temperature and handling, and states it is not made with natural rubber latex. Manufactured by Amgen, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.